An analysis of the sequence variability of meningococcal fHbp, NadA and NHBA over a 50-year period in the Netherlands

PLoS One. 2013 May 24;8(5):e65043. doi: 10.1371/journal.pone.0065043. Print 2013.

Abstract

Studies of meningococcal evolution and genetic population structure, including the long-term stability of non-random associations between variants of surface proteins, are essential for vaccine development. We analyzed the sequence variability of factor H-binding protein (fHbp), Neisserial Heparin-Binding Antigen (NHBA) and Neisseria adhesin A (NadA), three major antigens in the multicomponent meningococcal serogroup B vaccine 4CMenB. A panel of invasive isolates collected in the Netherlands over a period of 50 years was used. To our knowledge, this strain collection covers the longest time period of any collection available worldwide. Long-term persistence of several antigen sub/variants and of non-overlapping antigen sub/variant combinations was observed. Our data suggest that certain antigen sub/variants including those used in 4CMenB are conserved over time and promoted by selection.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adhesins, Bacterial / chemistry
  • Adhesins, Bacterial / genetics*
  • Antigens, Bacterial / chemistry
  • Antigens, Bacterial / genetics*
  • Antigens, Bacterial / immunology
  • Bacterial Proteins / chemistry
  • Bacterial Proteins / genetics*
  • Evolution, Molecular
  • Genetic Variation*
  • Multilocus Sequence Typing
  • Neisseria meningitidis, Serogroup B / classification
  • Neisseria meningitidis, Serogroup B / genetics*
  • Netherlands
  • Phylogeny
  • Time Factors

Substances

  • Adhesins, Bacterial
  • Antigens, Bacterial
  • Bacterial Proteins
  • NadA protein, Neisseria meningitidis
  • factor H-binding protein, Neisseria meningitidis

Grants and funding

This work was supported by Novartis Vaccines and Diagnostics. Authors affiliated to the funder were involved in study design, data collection and analysis and preparation of the manuscript.